TriLink’s CleanCap® AU analog is engineered for co-transcriptional capping of self-replicating RNAs derived from positive-sense RNA viruses, including Venezuelan equine encephalitis virus, Semliki Forest virus, and Sindbis virus. These viral genomes naturally begin with a 5′-AU sequence, and CleanCap AU produces Cap-1 RNAs that are better suited for eukaryotic translation than the Cap-0 RNAs generated by older co-transcriptional methods such as ARCA.
Compared with traditional enzymatic capping, CleanCap AU streamlines the production of self-amplifying RNAs, enhancing efficiency and scalability. The analog is fully compatible with TriLink’s portfolio of modified and unmodified nucleotides, offering flexibility for advanced RNA designs and therapeutic applications.
This technical note covers the following aspects:
- Vaccine development using alphavirus-adapted self-amplifying RNAs
- Basics of self-amplifying RNA replicons
- Challenges associated with capping alphavirus RNA
- Common capping methods for alphavirus RNA replicons and their usage considerations